Merck (NYSE:MRK) announced Wednesday that the U.S. Food and Drug Administration (FDA) granted priority review for its request ...

Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% ...

Welcome to Fierce Pharma's regulatory tracker for the second half of 2025. | In this tracker, Fierce Pharma is recording the ...

Priority Cycles' Current Plus e-commuter bike delivers good range and power, plus features a low-maintenance Gates belt-drive ...

The FDA approval of Vimkunya has given the chikungunya vaccine’s owner, Bavarian Nordic, an extra financial windfall. | The ...

The FDA is launching a program to reward companies with accelerated drug review and speedy agency feedback, if their actions ...

The upgraded Priority Current Plus goes fast and goes far with little effort, especially thanks to the new throttle. It’s a ...

The FDA announced a new national priority voucher plan that aims to cut drug review times, while Headspace launches direct-to ...

The FDA is introducing a new priority voucher program designed to shorten the drug review process from 10 to 12 months down to one or two months, according to the agency. The federal outfit’s ...

Rare disease priority review vouchers do not expire, but the program does and it must be renewed by Congress. Lawmakers failed to do so at the end of 2024. PRVs have also become commodities that ...